M2613

M2613 is a nonsteroidal estrogen derived from triphenylbromoethylene which was studied in the treatment of breast cancer in women in the 1940s but was never marketed.[1][2]

M2613
Clinical data
Other namesM-2613; Methoxyethoxy-triphenylbromoethylene
Drug classNonsteroidal estrogen
Identifiers
  • 1-Bromo-2-(p-ethoxyphenyl)-2-(p-methoxyphenyl)-1-phenylethylene
CAS Number
Chemical and physical data
FormulaC23H21BrO2
Molar mass409.323 g·mol−1

See also

References
  1. Walpole AL, Paterson E (October 1949). "Synthetic oestrogens in mammary cancer". Lancet. 2 (6583): 783–6. doi:10.1016/s0140-6736(49)91370-7. PMID 15391512.
  2. Jordan VC (February 2015). "The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer". Endocr. Relat. Cancer. 22 (1): R1–31. doi:10.1530/ERC-14-0448. PMC 4494663. PMID 25339261.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.